Which citrate solution minimizes metabolic chaos in kidney therapy?

NCT ID NCT07751861

First seen Aug 07, 2026 ยท Last updated Aug 07, 2026

Summary

This trial tests two different concentrations of citrate solution used to prevent blood clotting during continuous kidney replacement therapy in critically ill patients with acute kidney injury. The goal is to see which concentration leads to fewer metabolic complications, such as the need for extra electrolytes like magnesium, phosphate, or potassium. By comparing the low and high concentration solutions, the study aims to identify a safer approach for managing these patients.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
low concentrated citrate solution (18 mmol/L) or high concentrated citrate solution (136 mmol/L)
What this could lead to
If one citrate solution proves safer, it could become the standard choice for kidney replacement therapy in intensive care, reducing metabolic complications and improving patient outcomes.
What could go wrong
The trial is relatively small and focuses on a specific ICU population, so results may not apply broadly. Both solutions carry risks of electrolyte imbalances or acid-base disturbances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Antwerp University Hospital

    Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.